CME Empowerment Series 2025

Integrated Care from First Symptom to Survivorship
Join us in discussing the evolving role of primary care in the prevention, risk evaluation, screening, early detection, ongoing management of breast cancer and survivorship. With an emphasis on multidisciplinary collaboration, gain the knowledge and tools to foster evidence-based, compassionate care across the breast cancer continuum

Learn More About:

• Advancements in risk evaluation, genetics, personalised medicine & health equity
• Risk-based screening, early warning signs for concerning breast pathology, and referral processes
• Updates in breast cancer therapy: oncoplastic & minimally invasive breast surgery, preventative surgical options, improvements in radiotherapy and systemic therapy etc.
• Supporting patients through diagnosis, treatment, treatment related consequences, and survivorship
• Addressing psychosocial impact, advancements in rehabilitation, and quality of life post-treatment
• Shared care models for survivorship and chronic side effect management

This meeting is accredited by the Singapore Medical Council for 1 CME point.

Speakers

Dr Sabrina Ngaserin

Senior Consultant
Oncoplastic & Minimally Invasive Breast Surgeon
Breast Surgery Care Partners

Dr Tanujaa Rajasekaran

Senior Consultant
Medical Oncology
Parkway Cancer Centre

Dr Grace Kusumawidjaja

Senior Consultant
Haematology
Parkway Cancer Centre

The cornerstone of treatment for advanced prostate cancer is androgen deprivation therapy (ADT). In metastatic castration-sensitive prostate cancer (mCSPC), a large body of data supports early intensification of treatment by adding a novel hormonal agent (NHA) and/or chemotherapy.

Genomic testing should be offered to all patients with metastatic castration-resistant prostate cancer (mCRPC) to identify those with DNA repair pathway alterations or loss of mismatch repair protein expression, who may benefit from treatment with PARP inhibitors and immunotherapy, respectively.

The key focus of the session is on the role of targeting prostate-specific membrane antigen (PSMA). PSMA is widely expressed on the surface of most prostate cancer cells and can be harnessed to deliver PSMA-based radioligand therapy in mCRPC patients who have failed novel hormonal agents and/or chemotherapy. Data on treatment benefits and subgroups who derive greater benefit from this approach will be discussed.

Speakers and Panelists

Dr Wong Siew Wei

Senior Consultant
Medical Oncology
Parkway Cancer Centre

Dr Peh Wee Ming

Consultant Nuclear Medicine Physician
Parkway Radiology

Colorectal cancer (CRC) remains a leading cancer globally, with early detection and treatment playing a crucial role in improving patient outcomes.

In this “Hi Doc” CME Series III, we’ll be learning the latest approaches to CRC management, focusing on diagnostic procedures, surgical techniques and medical treatments.

Understand the role of colonoscopy in early detection and screening for CRC, surgical management, including the latest minimally invasive procedures and strategies for optimising patient recovery and the medical management for both localised and metastatic CRC.

Speakers

Dr Zee Ying Kiat

Senior Consultant
Medical Oncology
Parkway Cancer Centre

Dr Ho Kok Sun

Consultant Colorectal & General Surgeon
Ho Kok Sun Colorectal